Retifanlimab Approved for Anal Cancer Free

Tbe FDA approved retifanlimab-dlwr (Zynyz; Incyte), a PD-1-targeting mAb, in combination with chemotherapy for patients with inoperable or metastatic squamous cell carcinoma of the anal canal (SCAC). In the phase III, POD1UM-303/InterAACT 2, which enrolled 308 patients with SCAC, the 154 patients taking retifanlimab had a median 9.3 months without disease progression, compared with 7.4 months among the 154 who received a placebo. Overall survival results were not statistically significant.Retifanlimab is also approved for patients with Merkel cell carcinoma, a rare and aggressive form of skin cancer.